2) bcr-abl gene
bcr-abl基因
3) bcr/abl oncogene
bcr/abl融合癌基因
4) bcr/abl fusion gene
bcr/abl融合基因
1.
Expression of bcr/abl fusion gene in chronic myeloid leukemia and its clinical significance;
bcr/abl融合基因在慢性粒细胞白血病中的表达及临床意义
2.
Establishment and application of BCR/ABL fusion gene by RT-PCR in situ detection method;
细胞原位RT-PCR检测BCR/ABL融合基因方法的建立与应用
3.
Significance of detection of Ph1 chromosome and bcr/abl fusion gene in chronic myelocytic leukemia;
Ph1染色体及bcr/abl融合基因检测在慢性粒细胞白血病中的诊断意义
5) bcr-abl fusion gene
bcr-abl融合基因
1.
Quantitative detection of TREC and bcr-abl fusion gene transcripts in peripheral blood from 15 CML patients were preformed by real-time PCR.
实时定量PCR检测15例CML-CP患者外周血TREC含量及bcr-abl融合基因转录本的水平,并追踪检测6例患者bcr-abl水平的变化。
2.
To establish SP2/0 cell line H-2~d stably expressing bcr-abl fusion gene fragment, the bcr-abl fusion gene was subcloned into retroviral vector pLXSN from pGEMbcr-abl.
为了建立稳定表达bcr-abl融合基因片段的SP2/0细胞系,从重组克隆载体pGEMbcr-abl中酶切出bcr-abl融合基因片段,并将其亚克隆进逆转录病毒载体pLXSN中。
6) Bcr/Abl gene
Bcr/Abl融合基因
1.
Results The apoptosis rates of K-562 cells were gradually increased,while the expressions of both Bcr/Abl gene and p210 protein were declin.
目的探讨青黛复方对K-562细胞调亡、Bcr/Abl融合基因及p210蛋白的影响。
2.
5> 10~9/L and PLT was 16d up to >20 10~9/L;the blood type B was 17d began to transform, the sex chromosome was XX by STR method; the bcr/abl gene.
5×109/L,血小板>20×109/L的时间分别为+13d、+16d,+17d患者的血型由O型转变为供者的B型,并经STR复检证实患者的性染色体由XY转为供者型的性染色体XX;移植过程中未见GVHD、VOD等严重并发症,骨髓细胞bcr/abl融合基因于+27d检查完全消失,+100d再次复查仍为阴性。
补充资料：ABL
分子式：C6H8O3
分子量：128.13
CAS号：517-23-7
性质：密度1.185。沸点107-108°C (5 mmHg)。折射率1.4585。闪点140°C。水溶性310 g/L (20°C)。
分子量：128.13
CAS号：517-23-7
性质：密度1.185。沸点107-108°C (5 mmHg)。折射率1.4585。闪点140°C。水溶性310 g/L (20°C)。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条